Simplified Co-extraction of total Nucleic Acids from Respiratory Samples for detection of Mycobacterium tuberculosis and SARS-CoV-2 optimized for compatibility across Diagnostic Platforms
Preprint
Abstract
Tuberculosis (TB) and COVID-19 are leading infectious diseases with high mortality, caused by Mycobacterium tuberculosis ( Mtb ) and SARS-CoV-2 (SC2) , respectively. Co-infection is common but is often undiagnosed as it is challenging to process both pathogens from a single sample. In this study, we present a simple and efficient method for co-extracting nucleic acids (NA) from these two distinct respiratory pathogens for downstream diagnostic testing. We evaluated three different nucleic acid amplification (NAA)-based platforms, LightCycler480 (LC480) qPCR, Qiacuity digital PCR (dPCR), and Cytation3 for CRISPR-Cas13a-based SHINE-TB/SC2 detection assays. Chelex-100 chelating resin-based boiling preparation method was optimized for Mtb NA extraction from saliva and sputum. Saliva showed compatibility with all three platforms, with sensitivity as low as 100 CFU/ml (or 2 genomic copies/µl). This method worked well for sputum using dPCR at 100% (21/21) positivity, though the CRISPR-based SHINE-TB assay showed more variability and sensitivity to sputum inhibitor carry-over, resulting in an 81% positive rate (17/21). Diluting sputum with TE buffer (1:1) improved the detection (2/4). Extraction efficiency of our method was 48%, 62.2%, 86.4% and 99.3% for concentrations 10 5 , 10 4 , 10 3 and 10 CFU/ml, respectively. The dynamic range for Mtb spiked in pooled sputum showed 100% detection (N=8) at ≥10 3 CFU/ml with all three methods. Dual-pathogen co-extraction and detection of SC2 (10 5 PFU/ml) and Mtb (10 5 CFU/ml) in salivary sputum was successful using CRISPR-Cas13a assays. We have developed a rapid and efficient co-extraction method for multi-pathogen testing across diagnostic platforms and believe this is the first protocol optimized to co-extract Mtb and SARS-CoV-2 from a single sample.Keywords
This publication has 42 references indexed in Scilit:
- Detection of Mycobacterium tuberculosis complex in saliva by quantitative PCR: A potential alternative specimen for pulmonary tuberculosis diagnosisTuberculosis, 2024
- Diagnostic yield as an important metric for the evaluation of novel tuberculosis tests: rationale and guidance for future researchThe Lancet Global Health, 2024
- Integrating molecular and radiological screening tools during community-based active case-finding for tuberculosis and COVID-19 in southern AfricaInternational Journal of Infectious Diseases, 2024
- Diagnostic performance, stability, and acceptability of self-collected saliva without additives for SARS-CoV-2 molecular diagnosisEuropean Journal of Clinical Microbiology & Infectious Diseases, 2024
- Oral swabs with a rapid molecular diagnostic test for pulmonary tuberculosis in adults and children: a systematic reviewThe Lancet Global Health, 2023
- WHO's Global Tuberculosis Report 2022The Lancet Microbe, 2022
- Global impact of COVID-19 on childhood tuberculosis: an analysis of notification dataThe Lancet Global Health, 2022
- CRISPR-Cas systems for diagnosing infectious diseasesMethods, 2022
- The intersecting pandemics of tuberculosis and COVID-19: population-level and patient-level impact, clinical presentation, and corrective interventionsThe Lancet Respiratory Medicine, 2022
- TB-QUICK: CRISPR-Cas12b-assisted rapid and sensitive detection of Mycobacterium tuberculosisJournal of Infection, 2021